Opinion

Video

Full Range of Vision IOLs for Patients Wanting Spectacle Independence

A panelist discusses how he managed a 57-year-old tennis player with dry eye and Hashimoto thyroiditis by selecting a Toric enVista IOL for her refractive lens exchange, noting the patient’s satisfaction despite a temporary market recall of the lens.

Video content above is prompted by the following:Refractive Lens Exchange in Patient With Dry Eye

Key Discussion Topics

  • Complex patient profile
    • A 57-year-old woman with Hashimoto thyroiditis and dry eye
    • Low hyperope with trace nuclear sclerosis (refractive lens exchange candidate)
    • Avid tennis player requiring good stereopsis
    • Contact lens intolerant with dependence on reading glasses over contacts
  • Preoperative management
    • Preoperative optimization of ocular surface to improve topography
    • Inferior steepening on topography related to dry eye, not keratoconus
  • Lens selection considerations
    • Monovision contraindicated due to tennis requiring stereopsis
    • Extended depth of focus lenses insufficient for patient’s reading needs
    • Consultation with Canadian colleagues regarding enVista intraocular lens (IOL) performance in patients with dry eye

Notable Insights and Outcomes

  • Dell observed rapid visual recovery with enVista IOLs even in suboptimal corneal conditions
  • Patient received a Toric enVista IOL (placed at axis 326°, 25°)
  • On postoperative day 1, coinciding with a voluntary recall of the enVista IOL, patient reported excellent uncorrected distance and near vision
  • At 1-week follow-up, patient remained satisfied despite the recall
  • The subsequent reintroduction of enVista to the market allowed for potential matching IOL placement in the fellow eye

Concluding Observations

  • Late laser vision correction enhancements remain complicated but increasingly important
  • PRK is likely the best option for enhancement after laser vision correction, though still imperfect
  • Modern IOL designs have made refractive precision critical in this demanding patient population

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
© 2025 MJH Life Sciences

All rights reserved.